Composition and application thereof in preparation of anti-aging products
By applying collagen compositions in specific proportions to cosmetics and skincare products, the problems of high cost and limited effectiveness of existing anti-aging products are solved, achieving a safe and efficient anti-aging effect that significantly promotes collagen expression at lower concentrations.
Patent Information
- Application Number
- CN202411114203.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-22
AI Technical Summary
Existing anti-aging products are expensive and have limited effects, making it difficult to effectively promote collagen production.
A specific ratio of type I, III, IV, V, VII, and XXI collagen compositions was used, and the ratio was determined through skin tissue transcriptome data analysis. These compositions were then used in cosmetics and skincare products to promote collagen expression in fibroblasts.
It significantly promotes collagen expression at low concentrations, providing a safe and effective anti-aging solution. The safety of the composition was verified through cytotoxicity experiments.
Smart Images

Figure CN118986770A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of cosmetics, and in particular to a composition and application thereof in the preparation of anti-aging products. Background Art
[0002] With the development of society and the improvement of people's living standards, anti-aging has become an important research direction in the field of cosmetics and medical beauty. As the main component of skin structure, the content and quality of collagen directly affect the elasticity and firmness of the skin. As we age, the collagen in the skin gradually decreases, leading to aging phenomena such as wrinkles and sagging. Therefore, the development of products that can promote collagen production or supplement collagen is of great significance for anti-aging.
[0003] The anti-aging products currently on the market have limitations such as high cost and limited anti-aging effects.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] The object of the present invention is to provide a composition and application thereof in preparing anti-aging products.
[0006] The present invention is achieved in that:
[0007] In a first aspect, an embodiment of the present invention provides a composition, which comprises, by weight: 6 to 13 parts of type I collagen, 2 to 7 parts of type III collagen, 5 to 12 parts of type IV collagen, 4 to 9 parts of type V collagen, 1 to 6 parts of type VII collagen and 1 to 5 parts of type XXI collagen.
[0008] In a second aspect, an embodiment of the present invention provides a skin care product or cosmetic, the active ingredient of which includes the composition described in the above embodiment.
[0009] In a third aspect, embodiments of the present invention provide use of the composition described in the preceding embodiments in the preparation of anti-aging products.
[0010] In a fourth aspect, embodiments of the present invention provide use of the composition as described in the preceding embodiments in promoting the expression level of collagen or preparing a product for promoting the expression level of collagen.
[0011] The present invention has the following beneficial effects:
[0012] The present invention provides a novel collagen composition, which achieves synergistic effect through specific collagen types and ratios, and achieves significant anti-aging effects at a lower concentration. The collagen composition of the present invention can not only promote the expression of collagen in fibroblasts, but also has been verified by cytotoxicity experiments to ensure its safety and effectiveness. By applying the collagen composition to cosmetics and skin care products, a safer and more efficient anti-aging solution can be provided to consumers. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0014] Figure 1 It is the sample cell viability curve;
[0015] Figure 2 is the histogram of type I collagen expression level;
[0016] Figure 3 is the histogram of type III collagen expression level;
[0017] Figure 4 is the histogram of type IV collagen expression level;
[0018] Figure 5 is the histogram of type V collagen expression level;
[0019] Figure 6 is the histogram of type VII collagen gene expression level;
[0020] Figure 7 is the histogram of type XVII collagen gene expression level;
[0021] Figure 8 is the histogram of type XXI collagen gene expression level;
[0022] Fig. 9 This is a radar chart of collagen growth promotion by different collagen compound combinations. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0024] In view of the deficiencies of the prior art, the present invention analyzes the transcriptome data of skin tissues and simulates the collagen levels of four age groups, namely infants, teenagers, middle-aged and elderly people, to determine the specific combination ratio of the seven collagens, achieve synergistic effects, and achieve significant anti-aging effects at lower concentrations. The collagen composition of the present invention can promote the expression of type I, type III, type IV, type V and type XXI collagen in fibroblasts, and is significantly superior to other collagen combinations in terms of collagen growth-promoting levels and collagen types, thereby having a more excellent skin anti-aging ability; and its safety and effectiveness have been verified by cytotoxicity experiments. By applying the collagen composition to cosmetics and skin care products, a safer and more efficient anti-aging solution can be provided to consumers.
[0025] On the one hand, an embodiment of the present invention provides a composition, which includes, by weight: 6 to 13 parts of type I collagen, 2 to 7 parts of type III collagen, 5 to 12 parts of type IV collagen, 4 to 9 parts of type V collagen, 1 to 6 parts of type VII collagen and 1 to 5 parts of type XXI collagen.
[0026] In some embodiments, the weight proportions of type I collagen can be any one or more of 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, and 13 parts.
[0027] In some embodiments, the weight proportions of type III collagen can be any one or more of 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, and 7 parts.
[0028] In some embodiments, the weight proportions of type IV collagen can be any one or more of 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, and 12 parts.
[0029] In some embodiments, the weight proportions of type V collagen can be any one or more of 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, and 9 parts.
[0030] In some embodiments, the weight percentage of type VII collagen can be any one or more of 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 parts.
[0031] In some embodiments, the weight percentage of type XXI collagen can be any one or more of 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 parts.
[0032] In some embodiments, the composition further comprises: type XVII collagen.
[0033] Cytotoxicity experiments have shown that the several collagen combinations in the composition provided in the embodiments of the present invention do not show cytotoxicity, thus ensuring its safety.
[0034] In some embodiments, the composition comprises, by weight: 6 to 13 parts of type I collagen, 2 to 7 parts of type III collagen, 5 to 12 parts of type IV collagen, 4 to 9 parts of type V collagen, 1 to 6 parts of type VII collagen, 1 to 4 parts of type XVII collagen and 1 to 5 parts of type XXI collagen.
[0035] In some embodiments, the weight percentage of type XVII collagen can be any one or more of 1, 1.5, 2, 2.5, 3, 3.5, and 4 parts.
[0036] In some embodiments, the composition comprises, by weight: 8 to 11 parts of type I collagen, 4 to 5 parts of type III collagen, 7 to 10 parts of type IV collagen, 6 to 7 parts of type V collagen, 3 to 4 parts of type VII collagen, 1 to 3 parts of type XVII collagen and 2 to 3 parts of type XXI collagen.
[0037] In some embodiments, the total protein concentration of collagen in the composition is 1 to 1000 ppm, specifically any one of 1, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 ppm or a range between any two of them.
[0038] In some embodiments, in the composition, the weight ratios of collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VII, collagen type XVII, and collagen type XXI may be 9:4:7:7:3:2:3, 8:4:9:6:4:2:2, 9:4:10:6:4:2:2, and 11:5:10:7:3:0:2. These specific ratios are precisely determined based on skin tissue transcriptome data to ensure that excellent anti-aging effects can be achieved at lower concentrations.
[0039] On the other hand, an embodiment of the present invention provides a skin care product, the active ingredient of which includes the composition described in any of the above embodiments.
[0040] On the other hand, an embodiment of the present invention provides a cosmetic, the active ingredient of which includes the composition described in any of the above embodiments.
[0041] On the other hand, an embodiment of the present invention provides use of the composition as described in any of the above embodiments in the preparation of an anti-aging product.
[0042] In some embodiments, the anti-aging includes: any one or more of promoting the production of skin collagen, improving skin elasticity, and improving skin firmness.
[0043] In some embodiments, the product comprises: a skin care product and / or a cosmetic product.
[0044] In some embodiments, the skin care product comprises any one of: essence, lotion, facial cream, eye cream, facial mask, eye mask, hydrating spray, body lotion and hand cream.
[0045] In some embodiments, the cosmetic comprises: any one of lotion and liquid foundation.
[0046] In addition, an embodiment of the present invention also provides the use of the composition as described in any of the above embodiments in promoting the expression level of collagen or preparing a product for promoting the expression level of collagen.
[0047] In some embodiments, the collagen includes any one or more of type I collagen, type III collagen, type IV collagen, type V collagen and type XXI collagen.
[0048] In some embodiments, promoting the expression level of collagen includes: promoting the expression level of collagen in fibroblasts.
[0049] In some embodiments, the product for promoting the expression level of collagen includes a reagent or a kit.
[0050] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0051] In the following examples, the type I collagen, type III collagen, type IV collagen, type V collagen, type VII collagen and type XVII collagen used are recombinant type I collagen, recombinant type III collagen, recombinant type IV collagen, recombinant type V collagen, recombinant type VII collagen and recombinant type XVII collagen purchased from Juyuan Biotechnology; type XXI collagen is recombinant type XXI collagen purchased from Hemei Biotechnology.
[0052] Example 1
[0053] 1.1 Test Purpose
[0054] Based on preliminary laboratory data, the collagen levels in skin tissue of four age groups (infants, teenagers, middle-aged and elderly) were analyzed, the proportion of collagen combinations was determined by simulation, and recombinant collagen raw materials that can be provided by cosmetic raw material suppliers were selected for analysis and mapping.
[0055] 1.2 Test Method
[0056] (1) Data screening: Screen out differentially expressed collagen genes from differentially expressed genes.
[0057] (2) Collagen ratio analysis: Based on the expression level of collagen, the collagen ratio was determined by the minimum standardization-decimal counting retention method-integerization analysis method.
[0058] (3) Collagen combination design: Based on the ratio of collagen levels in four age groups, we simulate and design collagen combinations with different ratios in order to achieve the best anti-aging effect.
[0059] 1.3 Test Results
[0060] (1) The results of collagen levels in the four age groups are shown in Table 1, which shows the collagen levels in the four groups.
[0061] Table 1 Levels of 7 types of collagen in 4 groups
[0062] Collagen Type Infant Group Junior Group Middle-aged group Elderly Group Collagen Type I 34.65 35.94 35.67 38.60 Type III collagen 13.95 16.18 15.69 15.78 Type IV collagen 27.96 38.50 39.48 35.19 Type V collagen 25.88 24.44 23.63 24.69 Type VII collagen 12.77 15.64 14.82 11.26 Type XVII collagen 7.93 10.22 8.35 0.00 Collagen type XXI 11.12 8.89 7.61 6.93
[0063] (2) Based on the data analysis results, the proportion of collagen levels in four age groups was simulated to form a collagen composition.
[0064] Table 2 Combination ratio of 4 groups of collagen (total concentration: 70ppm)
[0065]
[0066]
[0067] Example 2
[0068] 2.1 Test Purpose
[0069] This test is divided into two parts. The first part is based on fibroblasts to carry out cytotoxicity testing to determine the safe dosing concentration of the collagen combination on fibroblasts. The second part is to detect the gene expression levels of type I collagen, type III collagen, type IV collagen, type V collagen, type VII collagen, type XVII collagen and type XXI collagen after the fibroblasts are treated with the collagen combination to comprehensively evaluate the anti-aging effect of the collagen combination.
[0070] 2.2 Test materials
[0071] 2.2.1 Test cells
[0072] The cells used in this test were fibroblasts purchased from Sciencell.
[0073] 2.2.2 Main reagents
[0074]
[0075] 2.2.3 Main consumables
[0076]
[0077] 2.2.4 Main equipment
[0078] Device Name brand model Biological Safety Cabinets Thermo Fisher Scientific <![CDATA[MSC-Advantage TM ]]> Cell culture incubator Thermo Fisher Scientific BB150 Centrifuge Thermo Fisher Scientific Sorvall ST8 Refrigerated centrifuge Thermo Fisher Scientific H1650 Inverted microscope Olympus CKX41 Cell Counter Countstar Mira FL Ultra-micro UV spectrophotometer Thermo Fisher Scientific NanoDrop One Gradient PCR instrument Takara TP600 Real-time fluorescence quantitative PCR system Applied Biosystems StepOnePlus
[0079] 2.2.5 Sample information
[0080] Table 3 Sample information
[0081]
[0082]
[0083] 2.3 Fibroblast toxicity test
[0084] 2.3.1 Test Method
[0085] (1) Cell treatment: Remove cells from the incubator, discard old culture medium, add 10 mL PBS to wash once, and discard PBS. Add 1 mL pancreatin and place in the incubator for digestion for 1 min. After digestion, add 3 mL complete culture medium to terminate digestion, use a pipette to gently blow off the cells at the bottom of the culture dish, and transfer the cell suspension to a 15 mL centrifuge tube. Centrifuge at 1000 rpm for 5 min. After centrifugation, discard the supernatant, add 1 mL complete culture medium and gently blow to mix.
[0086] (2) Cell seeding: Adjust the cell density to 3×10 4 / mL, inoculated into 96-well plates with a spray gun, 100μL per well. Add an equal volume of culture medium without cells to the blank group, and add an equal volume of PBS to the outermost circle to prevent the evaporation of the culture medium from affecting the experimental results, and finally place it in an incubator for 24h.
[0087] (3) Sample treatment: Weigh 1 mg of powdered sample into a 15 mL centrifuge tube, add 1 mL of PBS, and the sample concentration is now 1000 μg / mL (ppm), and vortex to mix. Add PBS to dilute the liquid sample to 0.1% (1000 ppm) according to the original concentration. After mixing all samples, filter through a 0.22 μm filter membrane. According to experimental needs, dilute the sample with PBS to different concentrations, such as 500, 250, 125, 62, 31, 15, 7 ppm.
[0088] (4) Solution preparation: Prepare sample working solutions of different concentrations (total concentration: 70 ppm) according to the test concentration setting table shown in Table 4.
[0089] Table 4 Test concentration setting table
[0090]
[0091]
[0092] (5) Sample addition treatment: When the cell plating rate in the 96-well plate reaches 40% to 60%, the drug is administered. 200 μL of FM culture medium is added to each well of the solvent control group; 200 μL of culture medium containing the corresponding concentration of sample is added to each well of the sample group; the blank group has no cell inoculation and only 200 μL of cell culture medium is added. After the treatment is completed, the 96-well plate is placed in an incubator (37°C, 5% CO 2 ) for 24 h.
[0093] (6) Detection: Dilute the CCK8 reagent with complete culture medium at a ratio of 1:10 and mix thoroughly. Aspirate the old culture medium in the 96-well cell culture plate, add 100 μL of the diluted CCK8 reagent to each well, and culture in an incubator for 2.5 hours. Turn on the microplate reader, set the dual wavelength, Lm1 to 450nm, Lm2 to 650nm, and perform detection.
[0094] (7) Data processing: The average absorbance values of the blank group and the control group were calculated and recorded as Ab and Ac, respectively. The formula for calculating cell viability was: cell viability (%) = (absorbance value - Ab) / (Ac - Ab) × 100%.
[0095] 2.3.2 Test Results
[0096] The results are shown in Table 5. Figure 1 , Table 5 shows the CCK8 test results of the samples, Figure 1 This is the sample cell viability curve.
[0097] Table 5 Sample CCK8 detection results
[0098]
[0099] From Table 5, Figure 1 It can be seen that the combinations of collagens I, III, IV, V, VII, XVII and XXI showed no obvious cytotoxicity to fibroblasts within the selected combined concentration range.
[0100] 2.4 Collagen I, III, IV, V, VII, XVII and XXI gene level test
[0101] 2.4.1 Test Method
[0102] (1) Cell inoculation: Remove the cells from the incubator, discard the old culture medium, and add 10 mL of PBS to wash once. After discarding the PBS, add 1.5 mL of trypsin and place in the incubator for digestion for about 1 minute. After digestion, add 4 mL of culture medium to terminate digestion, use a pipette to collect the cells into a 15 mL centrifuge tube, centrifuge at 1000 rpm for 5 minutes, discard the supernatant after centrifugation, and add 2 mL of culture medium to resuspend the cells. After thorough mixing, take 10 μL of cell suspension and mix with 10 μL of trypan blue, and use a cell counter to count. Take a new centrifuge tube, add fresh culture medium according to the required volume, and then add the cell suspension to adjust the cell density to 6×10 4 After thorough mixing, inoculate into 6-well plates and place in an incubator for 24 hours.
[0103] (2) Solution preparation: Test according to the sample information and test plan shown in Table 6.
[0104] Table 6 Test plan
[0105]
[0106]
[0107] (3) Sample addition treatment: According to the test scheme shown in Table 7, when the cell plating rate in the 6-well plate reaches 40% to 60%, 2 ml of FM culture medium is added to each well of the solvent control group; 2 mL of culture medium containing samples of corresponding concentrations is added to each well of the other sample groups, and 3 replicate wells are set for each group. After the treatment is completed, the 6-well plate is placed in an incubator (37°C, 5% CO2) and cultured for 24 hours.
[0108] (4) RNA extraction: RNA was extracted using the TaKaRa MiniBEST Universal RNA Extraction Kit and PrimeScript TM RT reagent Kit with gDNA Eraser reverse transcribes RNA into cDNA. Please refer to the instruction manual for detailed operation steps.
[0109] (5) Detection of gene expression: Using TB Premix Ex Taq TM The reagents were used to detect the gene expression levels of type I collagen, type III collagen, type IV collagen, type V collagen, type VII collagen, type XVII collagen, and type XXI collagen on the StepOnePlus real-time fluorescence quantitative PCR system. The specific steps and experimental system are detailed in the instructions.
[0110] 2.4.2 Statistical analysis of results
[0111] GraphPad Prism was used for graphing, and the results were expressed as Mean ± SD. t-test was used for statistical analysis between groups. P < 0.05 was considered to be significantly different, and P < 0.01 was considered to be extremely significantly different.
[0112] 2.4.3 Test Results
[0113] The results are shown in Table 7. Figure 2 to Figure 8 , Table 7 is a summary table of the gene expression detection results of type I collagen, type III collagen, type IV collagen, type V collagen, type VII collagen, type XVII collagen and type XXI collagen.
[0114] Table 7 Summary of collagen gene content detection results
[0115]
[0116]
[0117]
[0118] As can be seen from Table 7, the "baby"-like collagen ratio group uses a collagen compound with a concentration ratio of 9:4:7:7:3:2:3 for type I: type III: type IV: type V: type VII: type XVII: type XXI, which has a significant promoting effect on type I, type III, type IV, type V and type XXI collagen. Compared with the control equal ratio group, the collagen combination under this concentration ratio has a more significant and powerful collagen growth-promoting function. Therefore, it can be considered that the lower concentration of type I, type III, type IV, type V, type VII, type XVII and type XXI collagen compound in the "baby"-like collagen ratio group has anti-aging effects ( Figure 2 to Figure 8 ).
[0119] The collagen ratio group simulating "middle-aged" has a significant promoting effect on type IV collagen with a collagen compound with a concentration ratio of 9:4:10:6:4:2:2 for type I: type III: type IV: type V: type VII: type XVII: type XXI. Therefore, it can be considered that the lower concentration of type I, type III, type IV, type V, type VII, type XVII and type XXI collagen in the group simulating "middle-aged" has an anti-aging effect ( Figure 2 to Figure 8 ).
[0120] The collagen ratio group simulating the “senior age” has a significant promoting effect on type V collagen with a collagen compound of type I: type III: type IV: type V: type VII: type XVII: type XXI concentration ratio of 11:5:10:7:3:0:2. Therefore, it can be considered that the lower concentration of type I, type III, type IV, type V, type VII, type XVII and type XXI collagen compound in the “senior age” collagen ratio group has potential anti-aging effects ( Figure 2 to Figure 8 ).
[0121] The collagen compound with a concentration ratio of 8:4:9:6:4:2:2 for type I: type III: type IV: type V: type VII: type XVII: type XXI in the group imitating the ratio of "juvenile" collagen had no significant promoting effect on seven types of collagen, including type I, type III, type IV, type V, type VII, type XVII and type XXI collagen. Therefore, it can be considered that the lower concentration of type I, type III, type IV, type V, type VII, type XVII and type XXI collagen compound in the group imitating the ratio of "juvenile" collagen does not have potential anti-aging effects ( Figure 2 to Figure 8 ).
[0122] To make the results more intuitive, the inventors drew a radar chart of collagen gene expression to highlight the great advantages of the combination of the seven collagen combinations that mimics the "baby" collagen ratio (9:4:7:7:3:2:3) in anti-aging effects ( Fig. 9 ).
[0123] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A composition, characterized in that In terms of weight, it comprises: 6 to 13 parts of type I collagen, 2 to 7 parts of type III collagen, 5 to 12 parts of type IV collagen, 4 to 9 parts of type V collagen, 1 to 6 parts of type VII collagen and 1 to 5 parts of type XXI collagen.
2. The composition according to claim 1, characterized in that The composition further comprises: type XVII collagen.
3. The composition according to claim 2, characterized in that In terms of weight, it includes: 6 to 13 parts of type I collagen, 2 to 7 parts of type III collagen, 5 to 12 parts of type IV collagen, 4 to 9 parts of type V collagen, 1 to 6 parts of type VII collagen, 1 to 4 parts of type XVII collagen and 1 to 5 parts of type XXI collagen.
4. The composition according to claim 3, characterized in that In terms of weight, it comprises: 8 to 11 parts of type I collagen, 4 to 5 parts of type III collagen, 7 to 10 parts of type IV collagen, 6 to 7 parts of type V collagen, 3 to 4 parts of type VII collagen, 1 to 3 parts of type XVII collagen and 2 to 3 parts of type XXI collagen.
5. A skin care product or cosmetic, characterized in that: The active ingredient comprises the composition according to any one of claims 1 to 4.
6. Use of the composition according to any one of claims 1 to 4 in the preparation of anti-aging products.
7. The use according to claim 6, characterized in that: The anti-aging includes: any one or more of promoting the production of skin collagen, improving skin elasticity and improving skin firmness.
8. Use of the composition according to any one of claims 1 to 4 in promoting the expression level of collagen or in preparing a product for promoting the expression level of collagen.
9. The use according to claim 8, characterized in that: The collagen includes any one or more of type I collagen, type III collagen, type IV collagen, type V collagen and type XXI collagen.
10. The use according to claim 8, characterized in that: The promoting the expression level of collagen includes: promoting the expression level of collagen in fibroblasts.
Citation Information
Patent Citations
Application of collagen composition in preparation of anti-aging product and external cosmetic containing collagen composition
CN115154356A
Composite collagen composition and preparation method thereof
CN115671390A
Collagen peptide with anti-wrinkle function
CN116162151A
Collagen complex and method for producing cosmetic composition containing the same
JP2022183243A
Cosmetic composition comprising an extracellular connective tissue matrix
US5055298A
Cited By
Anti-wrinkle composition, application, skin care product and anti-wrinkle essence cream
CN119280095A
Anti-wrinkle composition, use, skin care product, anti-wrinkle essence cream
CN119280095B
